Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WVE-120102 OLE in Huntington's Disease
NCT04617860Phase 2Terminated
- Sponsor
- Wave Life Sciences
- Start
- Sep 2019
- Primary completion
- Apr 2021
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 7
01
Overview
A Phase 2 trial of WVE-120102 in Huntington's disease (HD), sponsored by Wave Life Sciences. Started Sep 2019; status: terminated.
02
Drugs
WVE-120102
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT04617860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04617860.